Free tool
FAERS Monitor: Accolate
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020547 or its brand name (Accolate, Zafirlukast). Reports on generic versions are filed under their own applications.
Reports
907
Serious
477
53% of reports
Hospitalization
211
Death reported
44
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea110
- asthma96
- fatigue87
- drug ineffective65
- cough56
- nausea51
- pruritus49
- off label use48
- wheezing48
- headache47
- rash47
- pneumonia46
- dizziness44
- pain43
- asthenia42
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 18 |
| 2005 | 10 |
| 2006 | 7 |
| 2007 | 9 |
| 2008 | 13 |
| 2009 | 14 |
| 2010 | 15 |
| 2011 | 14 |
| 2012 | 27 |
| 2013 | 25 |
| 2014 | 32 |
| 2015 | 38 |
| 2016 | 77 |
| 2017 | 51 |
| 2018 | 60 |
| 2019 | 51 |
| 2020 | 64 |
| 2021 | 68 |
| 2022 | 56 |
| 2023 | 53 |
| 2024 | 67 |
| 2025 | 83 |
| 2026 | 55 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,252 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| asthmaSignal | 96 | 19.7 | 16.3 | 1,694 |
| wheezingSignal | 48 | 18.8 | 14.3 | 792 |
| coughSignal | 56 | 4.6 | 3.6 | 158 |
| dyspnoeaSignal | 110 | 4.5 | 3.8 | 305 |
| pneumoniaSignal | 46 | 3.3 | 2.5 | 72 |
| pruritusSignal | 49 | 3.0 | 2.3 | 63 |
| fatigueSignal | 87 | 2.6 | 2.1 | 87 |
| astheniaSignal | 42 | 2.6 | 1.9 | 40 |
| rashSignal | 47 | 2.5 | 1.9 | 42 |
| dizzinessSignal | 44 | 2.0 | 1.5 | 23 |
| headache | 47 | 1.7 | 1.3 | 14 |
| pain | 43 | 1.6 | 1.2 | 10 |
| nausea | 51 | 1.5 | 1.1 | 8 |
| off label use | 48 | 1.3 | 1.0 | 3 |
| drug ineffective | 65 | 1.1 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.